People · Operator

WeiQing A. Zhou

Named in public records as an officer, director or promoter · active 2016–2018 · Pharmaceuticals

1
Companies
3
Filings
$278.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Fog Pharmaceuticals, Inc.PharmaceuticalsSeries D+$278.4M$3.1B2016
Operator network

WeiQing A. Zhou at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Corey S. Goodman · 4 companies · 1 sharedCorey S. GoodmanGregory L Verdine · 3 companies · 1 sharedGregory L VerdineLeon A. Chen · 2 companies · 1 sharedLeon A. ChenLeon M. Chen · 2 companies · 1 sharedLeon M. ChenWeiQing L Zhou · 2 companies · 1 sharedWeiQing L ZhouBarbara M. Weber · 1 companies · 1 sharedBarbara M. WeberEdward A. Fitzgerald · 1 companies · 1 sharedEdward A. Fitzger…Edward M. Fitzgerald · 1 companies · 1 sharedEdward M. Fitzger…Jeffrey A. Leerink · 1 companies · 1 sharedJeffrey A. LeerinkKrishna M. Yeshwant · 1 companies · 1 sharedKrishna M. Yeshwa…Michael L Aceti · 1 companies · 1 sharedMichael L AcetiRick M. Klausner · 1 companies · 1 sharedRick M. KlausnerWeiQing M. Zhou · 1 companies · 1 sharedWeiQing M. ZhouFog Pharmaceuticals, Inc. · $278.4M raisedFog Pharmaceuticals, …WeiQing A. ZhouWZ
WeiQing A. Zhou Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside WeiQing A. Zhou on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Corey S. Goodman14
Gregory L Verdine13
WeiQing L Zhou12
Leon M. Chen12
Leon A. Chen12
Jeffrey A. Leerink11
Edward M. Fitzgerald11
Barbara M. Weber11
Edward A. Fitzgerald11
Michael L Aceti11
WeiQing M. Zhou11
Krishna M. Yeshwant11
Rick M. Klausner11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.